| 43.2 -1.81 (-4.02%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.92 | 1-year : | 61.81 |
| Resists | First : | 45.31 | Second : | 52.92 |
| Pivot price | 37.52  |
|||
| Supports | First : | 36.73 | Second : | 31.44 |
| MAs | MA(5) : | 43.03 |
MA(20) : | 36.59 |
| MA(100) : | 37.13 |
MA(250) : | 42.39 |
|
| MACD | MACD : | 2.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 91.1 |
D(3) : | 91 |
| RSI | RSI(14): 65.8 |
|||
| 52-week | High : | 56.42 | Low : | 31.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CNMD ] has closed below upper band by 16.1%. Bollinger Bands are 170.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 45.11 - 45.35 | 45.35 - 45.55 |
| Low: | 42.1 - 42.37 | 42.37 - 42.59 |
| Close: | 42.77 - 43.21 | 43.21 - 43.59 |
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Fri, 17 Jul 2026
CONMED Corp (NYSE: CNMD) grants CFO stock options and RSUs - Stock Titan
Fri, 17 Jul 2026
CONMED (NYSE: CNMD) CFO John Gallagher reports zero common stock ownership - Stock Titan
Wed, 15 Jul 2026
CONMED (NYSE:CNMD) Downgraded by Zacks Research to Strong Sell - MarketBeat
Mon, 13 Jul 2026
CONMED (CNMD) Stock Trades Up, Here Is Why - Yahoo Finance
Mon, 13 Jul 2026
Medtech Surges On Buyout Rumors; Who's Behind The Bid? - Investor's Business Daily
Mon, 13 Jul 2026
CONMED Up Over 10%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 116.6 (%) |
| Shares Short | 2,530 (K) |
| Shares Short P.Month | 2,340 (K) |
| EPS | 1.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.75 |
| Profit Margin | 4 % |
| Operating Margin | 10.6 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 5.5 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 24.67 |
| Sales Per Share | 45.49 |
| EBITDA (p.s.) | 7.05 |
| Qtrly Earnings Growth | 136.8 % |
| Operating Cash Flow | 143 (M) |
| Levered Free Cash Flow | 127 (M) |
| PE Ratio | 23.35 |
| PEG Ratio | 1.8 |
| Price to Book value | 1.27 |
| Price to Sales | 0.94 |
| Price to Cash Flow | 9.11 |
| Dividend | 0.2 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|